Treatment pathways during the study
| Usual care (n=1155) | FF/VI (n=1081) | |
| Inhaler type initiated on, n (%) | ||
| n | 1155 | 1081 |
| DPI | 46 (4) | 1081 (100) |
| pMDI | 1004 (87) | 0 |
| DPI+pMDI | 25 (2) | 0 |
| Undetermined | 80 (7) | 0 |
| Number of patients on inhaler type path, n (%) | ||
| DPI during the whole period | 39 (3) | 916 (85) |
| pMDI during the whole period | 922 (80) | 0 |
| DPI → pMDI | 5 (<1) | 129 (12) |
| Undetermined | 60 (5) | 0 |
| pMDI → undetermined | 44 (4) | 0 |
| pMDI → DPI | 18 (2) | 0 |
| DPI → undetermined | 2 (<1) | 12 (1) |
| Other | 65 (6) | 24 (2) |
DPI, dry powder inhaler; FF/VI, fluticasone furoate/vilanterol; pMDI, pressurised metered dose inhaler.